Petroleum distillate solvents as risk factors for undifferentiated connective tissue disease (UCTD)

American Journal of Epidemiology

Volumn 149, Issue 8, 1999, Pages 761-770

  Lacey Jr , James V ^a   Garabrant, David H ^a,b   Laing, Timothy J ^b   Gillespie, Brenda W ^c   Mayes, Maureen D ^d   Cooper, Brenda C ^a   Schottenfeld, David ^a,b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Connective tissue diseases; Occupational exposure; Petroleum distillates; Rheumatic diseases; Solvents; Tetrachloroethylene; Trichloroethanes; Trichloroethylene; Undifferentiated

Indexed keywords

PETROLEUM DERIVATIVE; SOLVENT; TETRACHLOROETHYLENE; TRICHLOROETHANE; TRICHLOROETHYLENE;

ADULT; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTAMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OCCUPATIONAL EXPOSURE; PAINT INDUSTRY; POLYMERIZATION; POPULATION RESEARCH; RHEUMATIC DISEASE; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 0033561450     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009885     Document Type: Article

References (46)

1. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
3. Silman AJ. The 1987 revised American Rheumatism Association criteria for rheumatoid arthritis. Br J Rheumatol 1988;27:341-3.
4. Reichlin M. Undifferentiated connective tissue syndromes. In: Klippel JH, ed. Primer on the rheumatic diseases. Atlanta, GA: Arthritis Foundation, 1997:244-5.
5. Reichlin M. Undifferentiated connective tissue diseases, overlap syndromes, and mixed connective tissue diseases. In: Koopman WJ, ed. Arthritis and allied conditions: a textbook of rheumatology. Baltimore, MD: Williams & Wilkins, 1997:1309-18.
6. Christian CL. Connective tissue disease: overlap syndromes. In: Cohen A, Bennett JC, eds. Rheumatology and immunology. New York: Grune & Stratton, 1986:175-9.
7. Harper FE, Maricq HR, Turner RE, et al. A prospective study of Raynaud phenomenon and early connective tissue disease: a five-year report. Am J Med 1982;72:883-8.
8. LeRoy EC, Maricq H, Kahaleh M. Undifferentiated connective tissue disease syndrome. Arthritis Rheum 1980;23:341-3.
9. Seibold JR. Connective tissue diseases characterized by fibrosis. In. Kelley WN, Harris ED, Jr, Ruddy S, et al, eds. Textbook of rheumatology. Philadelphia: WB Saunders Co, 1993:1113-43.
10. Silman AJ, Hochberg MC. Occupational and environmental influences on scleroderma. Rheum Dis Clin North Am 1996;22:737-49.
11. Silver RM. Scleroderma and pseudoscleroderma: environmental exposure. In: Clements PJ, Furst DE, eds. Systemic sclerosis. Baltimore, MD: Williams & Wilkins, 1996:81-98.
12. Haustein UF, Ziegler V. Environmentally induced systemic sclerosis-like disorders. Int J Dermatol 1985;24:147-51.
13. Waller PA, Clauw D, Cupps T, et al. Fasciitis (not scleroderma) following prolonged exposure to an organic solvent (trichloroethylene). J Rheumatol 1994;21:1567-70.
14. Bottomley WW, Sheehan-Dare RA, Hughes P, et al. A sclerodermatous syndrome with unusual features following prolonged occupational exposure to organic solvents. Br J Dermatol 1993;128:203-6.
15. Saihan EM, Burton JL, Heaton KW. A new syndrome with pigmentation, scleroderma, gynaecomastia, Raynaud's phenomenon and peripheral neuropathy. Br J Dermatol 1978; 99:437-40.
16. Flindt-Hansen H, Isager H. Scleroderma after occupational exposure to trichloroethylene and trichloroethane. Acta Derm Venereol 1987;67:263-4.
17. Lockey JE, Kelly CR, Cannon GW, et al. Progressive systemic sclerosis associated with exposure to trichloroethylene. J Occup Environ Med 1987;29:493-6.
18. Kilburn KH, Warshaw RH. Prevalence of symptoms of systemic lupus erythematosus (SLE) and of fluorescent antinuclear antibodies associated with chronic exposure to trichloroethylene and other chemicals in well water. Environ Res 1992;57:1-9.
19. Schottenfeld D, Burns CJ, Gillespie BW, et al. The design of a population-based case-control study of systemic sclerosis (scleroderma): commentary on the University of Michigan study. J Clin Epidemiol 1995;48:583-6.
20. Lepkowski JM. Telephone sampling methods in the United States. In: Groves R, ed. Telephone survey methodology. New York: John Wiley & Sons, 1988:73-98.
21. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics 1994;50:1064-72.
22. Prentice RL, Breslow NE. Retrospective studies and future time models. Biometrica 1978;65:153-8.
23. Breslow NE, Day NE. Statistical methods in cancer research. Vol 1. The analysis of case-control studies. (IARC Scientific Publications No. 32). Lyon: International Agency for Research on Cancer, 1980.
24. SAS Institute Inc. SAS/STAT software: changes and enhancements through release 6.12. Cary, NC: SAS Institute, Inc, 1997.
25. Siemiatycki J, Fritschi L, Nadon L, et al. Reliability of an expert rating procedure for retrospective assessment of occupational exposures in community-based case-control studies. Am J Ind Med 1997;31:280-6.
26. Fritschi L, Siemiatycki J, Richardson L. Self-assessed versus expert-assessed occupational exposures. Am J Epidemiol 1996;144:521-7.
27. Cavender F. Aromatic hydrocarbons. In: Clayton GD, Clayton FE, eds. Patty's industrial hygiene and toxicology. New York: John Wiley & Sons, 1994:1301-1442.
28. Gleason MN, Gosselin RE, Hodge HC. Clinical toxicology of commercial products. Baltimore, MD: Williams & Wilkins, 1957.
29. Gosselin RE, Smith RP, Hodge HC. Clinical toxicology of commercial products. Baltimore, MD: Williams & Wilkins, 1984.
30. Czirjak L, Csiki Z, Nagy Z, et al. Exposure to chemicals and systemic sclerosis. (Letter). Ann Rheum Dis 1995;54:529.
31. Czirjak L, Bokk A, Csontos G, et al. Clinical findings in sixty one patients with progressive systemic sclerosis. Acta Derm Venereol 1989;69:533-6.
32. Czirjak L, Schlammadinger J, Szegedi G. Systemic sclerosis and exposure to trichloroethylene. (Letter). Dermatology 1993;186:236-7.
33. International Agency for Research on Cancer. Dry cleaning, some chlorinated solvents, and other industrial chemicals. (IARC Scientific Publications no. 63). Lyon: IARC, 1995.
34. Goldman JA. Connective tissue disease in people exposed to organic chemical solvents: systemic sclerosis (scleroderma) in dry cleaning plant and aircraft industry workers. J Clin Rheumatol 1996;2:185-90.
35. Walder BK. Do solvents cause scleroderma? Int J Dermatol 1983;22:157-8.
36. Yamakage A, Ishikawa H. Generalized morphea-like scleroderma occurring in people exposed to organic solvents. Dermatologica 1982;165:186-93.
37. Brasington RD, Thorpe-Swenson AJ. Systemic sclerosis associated with cutaneous exposure to solvent: case report and review of the literature. Arthritis Rheum 1991;34:631-3.
38. Bovenzi M, Barbone F, Betta A, et al. Scleroderma and occupational exposure. Scand J Work Environ Health 1995; 21:289-92.
39. Czirjak L, Danko K, Schlammadinger J, et al. Progressive systemic sclerosis occurring in patients exposed to chemicals. Int J Dermatol 1987;26:374-8.
40. Yáñez-Diaz S, Morán M, Unamuno P, et al. Silica and trichloroethylene-induced progressive systemic sclerosis. Dermatology 1992;184:98-102.
41. Alarcón GS, Williams GV, Singer JZ, et al. Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. J Rheumatol 1991;18:1332-9.
42. Clegg DO, Williams HJ, Singer JZ, et al. Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol 1991;18:1340-3.
43. Bulpitt KJ, Clements PJ, Lachenbruch PA, et al. Early undifferentiated connective tissue disease. III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993;118:602-9.
44. Alarcón GS, Willkens RF, Ward JR, et al. Early undifferentiated connective tissue disease. IV. Musculoskeletal manifestations in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of patients with well-established connective tissue diseases: followup analyses in patients with unexplained polyarthritis and patients with rheumatoid arthritis at baseline. Arthritis Rheum 1996; 39:403-14.
45. Mukerji B, Hardin JG. Undifferentiated, overlapping, and mixed connective tissue disease. Am J Med Sci 1993; 305:114-19.
46. Burns CJ, Laing TJ, Gillespie BW, et al. The epidemiology of scleroderma among women: assessment of risk from exposure to silicone and silica. J Rheumatol 1996;23:1904-11.